ALS Center Karolinska

Karolinska Institutet

The ALS Center Karolinska is a tertiary center for ALS and provides multidisciplinary care to ALS patients from the Greater Stockholm region. The Center also provides second opinion referrals from other Swedish patients and from ALS patients abroad. The Center conducts clinical trials for ALS via the ALS Treatment Center Karolinska (ALS Treat).

KarolinskaInstitutet_Logo
Karolinska Institutet

At the ALS Center Karolinska, we integrate clinical care with clinical- and preclinical research. Our main research focus is epidemiological research, risk and prognosis, quality of life, wet and dry biomarkers. All patients are part of the national Swedish MND registry, which is based in our clinic. To give patients and their families an opportunity to participate in clinical trials, the ALS Treatment Center Karolinska (ALS Treat) was established in cooperation with the clinic and conducts several clinical trials of ALS.

Contact
Location
Karolinska Universitetssjukhuset Huddinge, 18146, Stockholm, Sweden

Our Specialists

Caroline Ingre

Neurologist and Researcher

Dr. Caroline Ingre is a specialist in neuromuscular disease, and has been […]

Caroline Ingre
Current trials
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Read more
Active
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Active
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more